Last reviewed · How we verify
GB226
At a glance
| Generic name | GB226 |
|---|---|
| Also known as | Geptanolimab Injection, Geptanolimab, Recombinant humanized anti-PD-1 monoclonal antibody injection |
| Sponsor | Genor Biopharma Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors (PHASE1)
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC (PHASE1, PHASE2)
- Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (PHASE1)
- Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) (PHASE2)
- Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib (PHASE1)
- Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) (PHASE2)
- Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) (PHASE2)
- A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB226 CI brief — competitive landscape report
- GB226 updates RSS · CI watch RSS
- Genor Biopharma Co., Ltd. portfolio CI